Brain Imaging of DSP-2342

ConditionSCHIZOPHRENIA 1 (Disorder)

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-50

SponsorJohns Hopkins University

About this trial

The investigators aim to determine the effects of a novel drug on brain function and brain chemistry in patients with schizophrenia.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

right-handed, participants with schizophrenia between the ages of 18-50 years.

Disqualifiers

Current substance misuse

Pregnancy or breast feeding

Subjects with electrocardiographic abnormalities (particularly QTc prolongation)

Subjects with renal impairment

Trial design

Design model

Single group

Treatments tested in this trial

DSP-2342
Drug
a single oral dose of DSP-2342 on brain chemistry and brain activity in adults with schizophrenia.

Treatment groups

20 Participants

are divided into 1 treatment group

Group A: Evaluation of the neural effects of a single oral dose of DSP-2342Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

Glutamate levels (a.u.)

brain chemistry (e.g. glutamate levels in the prefrontal cortex) measured by Magnetic Resonance Spectroscopy (MRS)

Time frame

one MRS scan on the same day of drug administration (acute effect)

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Johns Hopkins University

Lead sponsor

Sumitomo Pharmaceuticals America

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: